Oqory is a clinical-stage biotechnology company specializing in developing advanced antibody-drug conjugates (ADCs) to treat multiple oncology indications. Our proprietary ADC discovery platform empowers us to deliver innovative therapies with enhanced efficacy, safety, and tolerability.
With a robust pipeline of clinical and preclinical candidates, including our lead asset OQY-3258, a best-in-class ADC targeting TROP2, we aim to transform cancer treatment outcomes for patients globally.
Founded in 2012, Oqory has established itself as a leader in ADC innovation, driving clinical progress and redefining possibilities in oncology.
Key Highlights:
Phase 3-ready lead asset OQY-3258 with robust clinical data and trials underway in China.
Advanced-stage pipeline addressing multiple oncology indications.
Integrated ADC discovery platform enabling end-to-end development of innovative therapies.
Join us in transforming the future of cancer care.
Company Details
- Employees
- 1
- Address
- San Diego, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Oncology, Antibody-Drug Conjugates (ADCs), Clinical Trials, Biotechnology, Cancer Research.
- HQ
- San Diego, CA
Oqory Inc. Questions
Oqory Inc.'s LinkedIn profile is https://www.linkedin.com/company/oqory
Oqory Inc. has
1 employees.
View email and phone details for 1
employees at Oqory Inc..
Oqory Inc.'s industry is
Biotechnology Research
Oqory Inc.'s top competitors are
Lassen Therapeutics,
Sab Bio,
Exelixis,
Abtis | 앱티스,
Crossignal Therapeutics Inc,
Beam Therapeutics,
Sorrento Therapeutics, Inc.,
Alphamab Oncology,
Apogee Therapeutics,
Turnstone Biologics.
Oqory Inc.'s categories are Biotechnology Research
